Zhejiang Hisun Pharmaceutical Co Ltd Total Liabilities
Zhejiang Hisun Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has total liabilities worth CN¥4.62 Billion CNY (≈ $675.70 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 600267 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zhejiang Hisun Pharmaceutical Co Ltd (1997–2025)
Total liabilities of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2025. This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Zhejiang Hisun Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Insignia Financial Ltd
AU:IFL
|
Australia | AU$1.70 Billion |
|
Webull Corp
NASDAQ:BULL
|
USA | $2.86 Billion |
|
Shandong Humon Smelting Co Ltd
SHE:002237
|
China | CN¥25.69 Billion |
|
Chicony Electronics Co Ltd
TW:2385
|
Taiwan | NT$57.36 Billion |
|
Medicover AB (publ)
ST:MCOV-B
|
Sweden | Skr20.09 Billion |
|
LEROY SEAFOOD GR.UNSP.ADR
F:Z1L0
|
Germany | €20.77 Billion |
|
Zhuzhou Hongda Electronics Corp Ltd Class A
SHE:300726
|
China | CN¥528.27 Million |
|
Kaynes Technology India Limited
NSE:KAYNES
|
India | Rs20.49 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zhejiang Hisun Pharmaceutical Co Ltd assets under control.
Liquidity & Leverage Metrics
Zhejiang Hisun Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Zhejiang Hisun Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Hisun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual total liabilities of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.20 Billion ≈ $907.24 Million |
-16.14% |
| 2024-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
-20.19% |
| 2023-12-31 | CN¥9.26 Billion ≈ $1.36 Billion |
-11.33% |
| 2022-12-31 | CN¥10.45 Billion ≈ $1.53 Billion |
-13.14% |
| 2021-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
-4.56% |
| 2020-12-31 | CN¥12.60 Billion ≈ $1.84 Billion |
-8.56% |
| 2019-12-31 | CN¥13.78 Billion ≈ $2.02 Billion |
-4.78% |
| 2018-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
+5.19% |
| 2017-12-31 | CN¥13.76 Billion ≈ $2.01 Billion |
+8.19% |
| 2016-12-31 | CN¥12.72 Billion ≈ $1.86 Billion |
+15.53% |
| 2015-12-31 | CN¥11.01 Billion ≈ $1.61 Billion |
+21.87% |
| 2014-12-31 | CN¥9.03 Billion ≈ $1.32 Billion |
+12.72% |
| 2013-12-31 | CN¥8.01 Billion ≈ $1.17 Billion |
+49.20% |
| 2012-12-31 | CN¥5.37 Billion ≈ $786.00 Million |
+47.67% |
| 2011-12-31 | CN¥3.64 Billion ≈ $532.27 Million |
+14.48% |
| 2010-12-31 | CN¥3.18 Billion ≈ $464.96 Million |
+14.79% |
| 2009-12-31 | CN¥2.77 Billion ≈ $405.06 Million |
+7.62% |
| 2008-12-31 | CN¥2.57 Billion ≈ $376.38 Million |
+59.90% |
| 2007-12-31 | CN¥1.61 Billion ≈ $235.38 Million |
+4.30% |
| 2006-12-31 | CN¥1.54 Billion ≈ $225.67 Million |
+11.92% |
| 2005-12-31 | CN¥1.38 Billion ≈ $201.63 Million |
+40.92% |
| 2004-12-31 | CN¥977.76 Million ≈ $143.08 Million |
+12.13% |
| 2003-12-31 | CN¥871.96 Million ≈ $127.59 Million |
+16.15% |
| 2002-12-31 | CN¥750.69 Million ≈ $109.85 Million |
+45.84% |
| 2001-12-31 | CN¥514.75 Million ≈ $75.32 Million |
+14.64% |
| 2000-12-31 | CN¥449.01 Million ≈ $65.70 Million |
+6.34% |
| 1999-12-31 | CN¥422.24 Million ≈ $61.79 Million |
+47.02% |
| 1998-12-31 | CN¥287.20 Million ≈ $42.03 Million |
+70.26% |
| 1997-12-31 | CN¥168.68 Million ≈ $24.68 Million |
-- |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more